CLAIMS

1. An antitumor agent combinedly comprising a liposome preparation obtainable by encapsulating oxaliplatin in a liposome, and a combination drug containing tegafur, gimeracil and oteracil potassium.

2. The antitumor agent according to Claim 1, wherein at least one lipid component that constitutes the liposome is phospholipid.

3. The antitumor agent according to Claim 2, wherein the membrane surface of the liposome is modified with polyethylene glycol, polyglycerin or cationic lipid.

4. The antitumor agent according to any one of Claims 1 to 3, wherein the oxaliplatin is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur.

5. The antitumor agent according to Claim 1, wherein the gimeracil is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur, and the oteracil potassium is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur in the combination drug containing tegafur, gimeracil and oteracil potassium.

6. The antitumor agent according to claim 1, wherein the antitumor agent is formed as a kit that comprises a liposome preparation containing oxaliplatin, and a combination drug containing tegafur, gimeracil and oteracil potassium.

7. The antitumor agent according to Claim 1, wherein the liposome preparation is administered intravenously, intraperitoneally, intramuscularly or subcutaneously, and the combination drug containing tegafur, gimeracil and oteracil potassium is administered orally.

8. An antitumor effect potentiator, which is a liposome preparation containing an effective amount of oxaliplatin in a liposome, for enhancing antitumor activity of a therapeutically effective amount of a combination drug containing tegafur, gimeracil and oteracil potassium.

9. The antitumor effect potentiator according to Claim 8, wherein at least one lipid component that constitutes the liposome is phospholipid.

10. The antitumor effect potentiator according to Claim 9, wherein the membrane surface of liposome is modified with polyethylene glycol, polyglycerin or cationic lipid.

11. The antitumor effect potentiator according to any one of Claims 8 to 10, wherein the oxaliplatin is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur.

12. The antitumor effect potentiator according to Claim 8, wherein the gimeracil is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur, and the oteracil potassium is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur, in the combination drug containing tegafur, gimeracil and oteracil potassium.

13. Use of a liposome preparation obtainable by encapsulating oxaliplatin in a liposome, and a combination drug containing tegafur, gimeracil and oteracil potassium for producing an antitumor agent.

14. Use of a liposome preparation obtainable by encapsulating oxaliplatin in a liposome for producing an antitumor effect potentiator.

CLAIMS

1. An antitumor agent combinedly comprising a liposome preparation obtainable by encapsulating oxaliplatin in a liposome, and a combination drug containing tegafur, gimeracil and oteracil potassium.

2. The antitumor agent according to claim 1, wherein at least one lipid component that constitutes the liposome is phospholipid.

3. The antitumor agent according to claim 2, wherein the membrane surface of the liposome is modified with polyethylene glycol, polyglycerin or cationic lipid.

4. The antitumor agent according to any one of claims 1 to 3, wherein the oxaliplatin is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur.

5. The antitumor agent according to any one of claims 1 to 4, wherein the gimeracil is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur, and the oteracil potassium is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur in the combination drug containing tegafur, gimeracil and oteracil potassium.

6. The antitumor agent according to claim 1, wherein the antitumor agent is formed as a kit that comprises a liposome preparation containing oxaliplatin, and a combination drug containing tegafur, gimeracil and oteracil potassium.

7. The antitumor agent according to claim 1, wherein the liposome preparation is administered intravenously, intraperitoneally, intramuscularly or subcutaneously, and the combination drug containing tegafur, gimeracil and oteracil potassium is administered orally.

8. A liposome preparation obtainable by encapsulating oxaliplatin in a liposome for use as an antitumor agent with a combination drug containing tegafur, gimeracil and oteracil potassium.

9. The liposome preparation according to claim 8, wherein at least one lipid component that constitutes the liposome is phospholipid.

10. The liposome preparation according to claim 9, wherein the membrane surface of liposome is modified with polyethylene glycol, polyglycerin or cationic lipid.

11. The liposome preparation according to any one of claims 8 to 10, wherein the oxaliplatin is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur.

12. The liposome preparation according to any one of claims 8 to 11, wherein the gimeracil is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur, and the oteracil potassium is used in a proportion of 0.1 to 5 mol per 1 mol of tegafur, in the combination drug containing tegafur, gimeracil and oteracil potassium.

13. Use of a liposome preparation obtainable by encapsulating oxaliplatin in a liposome, and a combination drug containing tegafur, gimeracil and oteracil potassium for producing an antitumor agent.

14. Use of a liposome preparation which contains oxaliplatin encapsulated in a liposome for the preparation of a medicament for treating cancer with a combination drug containing tegafur, gimeracil and oteracil potassium, wherein an effective dose of the liposome preparation and an effective dose of the combination drug containing tegafur, gimeracil and oteracil potassium is to be administered to a cancer patient.

15. A combination drug containing tegafur, gimeracil and oteracil potassium and a liposome preparation containing oxaliplatin encapsulated in a liposome for use in the treatment of cancer, wherein an effective dose of the liposome preparation and of the combination drug containing tegafur, gimeracil and oteracil potassium is to be administered to a cancer patient.

16. The antitumor agent according to any one of claims 1 to 7, the liposome preparation according to any one of claims 8 to 12, the use of a liposome preparation according to claims 13 or 14, or the combination drug of claim 15, wherein the liposome preparation is to be administered separately or concurrently with the combination drug containing tegafur, gimeracil and oteracil potassium.